Emmessar Biotech & Nutrition Ltd
Emmessar Biotech & Nutrition Ltd is a standalone healthcare-products and property-leasing company. It manufactures /trades a small VedaCeuticals portfolio and earns rent from sub-leasing its MIDC Taloja industrial land; FY26 filings report Healthcare and Rent on Leasehold Land as the only operating segments.[1]
- Market Cap ₹ 11.6 Cr.
- Current Price ₹ 23.3
- High / Low ₹ 36.2 / 18.4
- Stock P/E 29.8
- Book Value ₹ 16.2
- Dividend Yield 0.00 %
- ROCE 7.33 %
- ROE 5.56 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -44.4% over past five years.
- Company has a low return on equity of 6.71% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.40 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.37 | 0.33 | |
| 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.56 | 1.73 | 1.76 | |
| Operating Profit | -0.15 | -0.68 | 0.23 | -0.40 | -0.64 | -0.41 | 0.84 | -0.90 | -0.69 | -1.08 | -0.95 | -1.36 | -1.43 |
| OPM % | -6.85% | -34.34% | 8.81% | -31.50% | -101.59% | -12.06% | 12.02% | -250.00% | -67.65% | -192.86% | -155.74% | -367.57% | -433.33% |
| 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 2.01 | 2.04 | 2.04 | |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 |
| Profit before tax | -0.16 | -0.68 | 1.19 | 0.80 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.96 | 0.58 | 0.50 |
| Tax % | -25.00% | -30.88% | 0.00% | -15.00% | -82.76% | -2.70% | 36.00% | 48.39% | 47.42% | 7.41% | 66.67% | 24.14% | |
| -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.50 | 0.75 | 0.32 | 0.44 | 0.39 | |
| EPS in Rs | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.50 | 2.90 | 0.96 | 1.00 | 1.50 | 0.64 | 0.88 | 0.78 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -15% |
| 5 Years: | -44% |
| 3 Years: | -29% |
| TTM: | -48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -21% |
| 3 Years: | -4% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -8% |
| 3 Years: | -2% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 7% |
| Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Reserves | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 | 2.71 | 3.12 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.08 | 0.11 | 0.00 | 0.00 | |
| 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.71 | 1.66 | |
| Total Liabilities | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.42 | 9.78 |
| 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2.00 | 1.91 | 1.81 | 1.72 | |
| CWIP | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.60 | 8.05 | |
| Total Assets | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.42 | 9.78 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | 0.75 | 0.74 | 0.39 | 1.03 | 0.47 | 2.27 | 0.38 | 0.64 | 0.22 | 0.27 | ||
| 0.00 | -0.74 | -0.69 | -0.37 | -1.06 | 0.01 | -2.61 | -0.55 | -0.64 | -0.23 | -0.26 | ||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | ||
| Net Cash Flow | -0.01 | 0.01 | 0.05 | 0.01 | -0.03 | 0.48 | -0.34 | -0.17 | 0.00 | 0.00 | 0.02 | |
| Free Cash Flow | -0.01 | -0.06 | -0.04 | 0.39 | 1.03 | 0.47 | 1.96 | 0.35 | 0.64 | 0.22 | 0.26 | |
| CFO/OP | 7% | 343% | -198% | -61% | -251% | 68% | -284% | -46% | -57% | -25% | -11% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 141.51 | 10.14 | 3.58 | 13.04 | 11.97 | 19.73 |
| Inventory Days | 335.80 | 136.88 | 121.67 | 52.14 | 2,049.62 | 272.56 | 7.24 | 196.54 | 127.75 | 164.25 | 230.53 | 405.56 |
| Days Payable | 150.87 | 76.04 | 76.04 | 5.79 | 1,628.46 | 189.61 | 51.70 | 56.15 | 0.00 | 18.25 | 0.00 | 40.56 |
| Cash Conversion Cycle | 191.60 | 127.20 | 51.22 | 54.97 | 444.33 | 86.18 | 97.05 | 150.52 | 131.33 | 159.04 | 242.49 | 384.73 |
| Working Capital Days | 38.33 | 22.12 | 85.31 | 175.31 | 457.70 | 30.06 | 79.37 | -60.83 | 114.51 | 91.25 | 29.92 | 88.78 |
| ROCE % | -10.81% | -39.30% | 80.00% | 31.50% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% | 7.33% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Export of Goods (FOB Value) Rs Lakhs |
|
||||||||
| Lease Income (Rent on Leasehold Land) Rs Lakhs |
|||||||||
| Manufactured Goods Revenue Rs Lakhs |
|||||||||
| Traded Goods Revenue Rs Lakhs |
|||||||||
| Number of Permanent Employees count |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Newspaper Add
- Notice of 34th AGM sent; newspapers published for September 29, 2026 meeting.
-
Communication To Shareholders Whose Email Ids Are Not Registered
- Company dispatched FY2025-26 annual report and 34th AGM notice; AGM on September 29, 2026.
-
Communication Sent To Shareholders Holding Physical Shares
- Annual report and 34th AGM notice shared for FY2025-26; AGM on September 29, 2026.
-
Reg. 34 (1) Annual Report.
- 34th AGM on September 29, 2026; annual report filed, with MD and whole-time director reappointment proposals.
- Notice Of The 34Th Annnual General Meeting Of The Company To Be Held On September 29, 2026
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
EBNL is a global healthcare company
that manufactures and markets health
care & nutritional products. It fuses
various concepts & principles (both
ancient & modern) from Biophysics, Biochemistry, Biotechnology and
the Indian system of medicine AYUSH
(Ayurveda + Yoga + Unani + Siddha
+ Homeopathy) to create products.
This integration resulted in technology
called VedaCeuticals which forms
the foundation of all products of
EBNL